Kyle Chenet
Directeur Général chez 410 Medical, Inc.
Profil
Kyle Chenet is currently the Chief Executive Officer & Director at 410 Medical, Inc. He previously held positions as the Chief Executive Officer at Lq3 Pharmaceuticals, Inc., Director-Business Development at Biolex Therapeutics, Inc., Director-Worldwide Business Development at GSK Plc, Manager at Abbott Laboratories, Vice President-Corporate Development at Liquidia Technologies, Inc., and Vice President-Corporate Development at Envisia Therapeutics, Inc. He holds an MBA from Stanford University and an undergraduate degree from the University of Michigan.
Postes actifs de Kyle Chenet
| Sociétés | Poste | Début |
|---|---|---|
410 Medical, Inc.
 410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Directeur Général | - |
Anciens postes connus de Kyle Chenet
| Sociétés | Poste | Fin |
|---|---|---|
Biolex Therapeutics, Inc.
 Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Corporate Officer/Principal | - |
Lq3 Pharmaceuticals, Inc.
 Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Directeur Général | - |
| GSK PLC | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Formation de Kyle Chenet
| Stanford University | Masters Business Admin |
| University of Michigan | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 5 |
|---|---|
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Distribution Services |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Lq3 Pharmaceuticals, Inc.
Lq3 Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Lq3 Pharmaceuticals, Inc. develops innovative oral health therapies. It utilizes PRINT (Particle Replication In Non-Wetting Templates) technology to research and develop solutions for an assortment of oral health issues. The firm's technology offers many advantages, such as tunable release kinetics, targeting, improved drug loading, delivery of biologics and combination products. The company was founded in 2014 and is headquartered in Garland, TX. | Health Services |
410 Medical, Inc.
410 Medical, Inc. Medical SpecialtiesHealth Technology 410 Medical, Inc. operates as a medical device company. It develops LifeFlow for fluid resuscitation to help patients with life-threatening illnesses such as sepsis. The company was founded by Mark Donald Piehl and Luke Miller Roush in 2013 and is headquartered in Durham, NC. | Health Technology |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
